http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170104263-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fe76949cd566430d9d83a068bab21e1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aa2f1db1f21ab540beed087da47d142 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e313dd93a6ba4e01e05dc35b8087090 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b66b6fbe51b72e8069d5dade4bb2e9b |
| publicationDate | 2017-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170104263-A |
| titleOfInvention | Methods for screening anti-cancer drugs inhibiting interactions between AIMP2-DX2 and HSP70 |
| abstract | The present invention relates to an anticancer agent screening method for inhibiting the binding of AIMP2-DX2 to HSP70, and more particularly, to a method for screening an anti-cancer agent screening method which comprises contacting AIMP2-DX2 or a fragment thereof with HSP70 or a fragment thereof in the presence or absence of a test substance; Measuring the binding of AIMP2-DX2 and HSP70; Determining a change in the level of binding of AIMP2-DX2 and HSP70 by the test substance; Selecting a test substance that reduces the binding level of AIMP2-DX2 and HSP70; And identifying an anticancer activity of the selected test substance in a cell or an animal, and an anticancer composition comprising the anticancer agent selected by the method as an active ingredient. The present invention can be used to develop an anticancer agent of completely novel mechanism based on the discovery that HSP70 is a regulator that directly binds and stabilizes AIMP2-DX2 which is important for cancer development and progression. Also, the pharmaceutical composition for preventing or treating cancer, which comprises the anticancer agent selected as an active ingredient according to the method of the present invention, inhibits the expression of HSP70 or inhibits the binding of HSP70 to AIMP2-DX2, thereby lowering the level of AIMP2- Can effectively prevent the progression of cancer, and can be useful for developing cancer therapeutic agents. |
| priorityDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 644.